Skip Navigation



Annals of Oncology Advance Access published online on October 25, 2005
Annals of Oncology, doi:10.1093/annonc/mdj016
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/1/104    most recent
mdj016v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Socinski, M. A.
Right arrow Articles by Niell, H. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Socinski, M. A.
Right arrow Articles by Niell, H. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received May 4, 2005
Revised July 11, 2005
Accepted August 8, 2005

original article

A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer

M. A. Socinski 1*, A. Ivanova 1, K. Bakri 1, J. Wall 1, M. Q. Baggstrom 1, T. A. Hensing 2, A. Mears 1, M. Tynan 1, J. Beaumont 2, A. H. Peterman 2, and H. B. Niell 1

1 Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
2 Evanston Northwestern Healthcare and Northwestern University, Chicago, IL, USA

* To whom correspondence should be addressed.
M. A. Socinski, E-mail: socinski{at}med.unc.edu


  Abstract

Background: The optimal schedule of taxane administration has been an area of active interest in several recent clinical trials.

Methods: To address a pure schedule question, we randomized 161 patients with advanced stage IIIB or IV non-small-cell lung cancer (NSCLC) to either paclitaxel 225 mg/m2 every 3 weeks x 4 cycles or 75 mg/m2/week x 12 (cumulative dose on each arm = 900 mg/m2). Both arms received concurrent carboplatin AUC 6 every 3 weeks x 4 cycles.

Results: The two arms were well-balanced in terms of known prognostic factors. The overall response rate and survival outcomes were similar on the two arms. There was significantly more grade 3/4 thrombocytopenia and grade 2-4 anemia on the weekly arm but less severe myalgias/arthralgias and alopecia. No difference in the rates of peripheral neuropathy was observed; however, patients on the every 3 weeks arm reported significantly more taxane therapy-related side-effects on the functional assessment of cancer therapy taxane subscale.

Conclusions: This randomized trial exploring schedule-related issues with carboplatin/paclitaxel confirms the versatility of this regimen.

Keywords: carboplatin; non-small cell lung cancer; paclitaxel.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
K. Naoki, H. Kunikane, T. Fujii, S. Tsujimura, N. Hida, H. Okamoto, and K. Watanabe
Dose-escalating and Pharmacokinetic Study of a Weekly Combination of Paclitaxel and Carboplatin for Inoperable Non-small Cell Lung Cancer: JCOG 9910-DI
Jpn. J. Clin. Oncol., September 1, 2009; 39(9): 569 - 575.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
T. HIROSE, T. SUGIYAMA, S. KUSUMOTO, T. SHIRAI, M. NAKASHIMA, T. YAMAOKA, K. OKUDA, K. OGURA, T. OHNISHI, T. OHMORI, et al.
Phase II Study of the Combination of Nedaplatin and Weekly Paclitaxel in Patients with Advanced Non-small Cell Lung Cancer
Anticancer Res, May 1, 2009; 29(5): 1733 - 1738.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. P. Belani, S. Ramalingam, M. C. Perry, R. V. LaRocca, D. Rinaldi, P. S. Gable, and W. J. Tester
Randomized, Phase III Study of Weekly Paclitaxel in Combination With Carboplatin Versus Standard Every-3-Weeks Administration of Carboplatin and Paclitaxel for Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., January 20, 2008; 26(3): 468 - 473.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.